FABP4 and metabolic dysfunction-associated steatotic liver disease: Interestingly, though FABP4 is not expressed by LSECs under basal conditions, the exposure of these cells to conditions mimicking NAFLD (high concentrations of glucose, insulin, and VEGFA) led to a significant release of FABP4 protein, and FABP4 increased the cell viability and proliferation of hepatocytes, leading to the conclusion that FABP4 exerts pro-oncogenic effects [141].